<SEC-DOCUMENT>0001214659-26-005225.txt : 20260429
<SEC-HEADER>0001214659-26-005225.hdr.sgml : 20260429
<ACCEPTANCE-DATETIME>20260429131831
ACCESSION NUMBER:		0001214659-26-005225
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260429
DATE AS OF CHANGE:		20260429
EFFECTIVENESS DATE:		20260429

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		26913399

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Friends Fiduciary Corp
		CENTRAL INDEX KEY:			0001696940
		ORGANIZATION NAME:           	
		EIN:				231968136
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		1700 MARKET STREET
		STREET 2:		SUITE 1535
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		2152417272

	MAIL ADDRESS:	
		STREET 1:		1700 MARKET STREET
		STREET 2:		SUITE 1535
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>o429263px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notice of Exempt Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ff_logo.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF REGISTRANT: </B>Eli Lilly and Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF PERSON RELYING ON EXEMPTION: </B>Friends Fiduciary Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADDRESS OF PERSON RELYING ON EXEMPTION: </B>1700 Market Street,
Suite 1535, Philadelphia, PA 19103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated
under the Securities Exchange Act of 1934.&nbsp;The soliciting person does not beneficially own more than $5 million of the class of subject
securities, and the notice is therefore being provided on a voluntary basis.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This is not a solicitation of authority to vote
your proxy.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Please DO NOT send us your proxy card as it
will not be accepted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Shareholder Proposal:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholders request the Board of Directors adopt as policy, and
amend the bylaws as necessary, to require henceforth that the Chair of the Board of Directors, whenever possible, be an independent member
of the Board. This independence policy shall apply prospectively so as not to violate any contractual obligations. If the Board determines
that a Chair who was independent when selected is no longer independent, the Board shall select a new Chair who satisfies the requirements
of the policy within a reasonable amount of time. Compliance with this policy is waived if no independent director is available and willing
to serve as Chair. This policy would be phased in for the next chief executive officer (CEO) transition.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shareholder Proposal was filed by Mercy Investment
Services and Friends Fiduciary Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eli Lilly and Company (LLY) (&ldquo;Eli Lilly&rdquo;)
stands at a critical juncture, given the business risks created by the rising prices of the company&rsquo;s insulin products and allegations
of anti-competitive pricing behavior in the insulin market.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>i</SUP></FONT>
We urge shareholders to clearly signal to the Eli Lilly board that the long-term financial and reputational risks of its current strategy
outweigh any short-term financial benefits, by voting FOR Proposal 6 to require an independent chair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ELI LILLY FACES FINANCIAL, LEGAL AND REPUTATIONAL
RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As one of the three primary insulin makers worldwide,
Eli Lilly faces substantial financial, legal and reputational risks stemming from allegations that it has engaged in anti-competitive
pricing and related behavior in the insulin and GLP-1 markets. In January of this year, Strive Specialties sued the company and Novo Nordisk
claiming the drugmakers entered into exclusive agreements with telehealth providers, which were then barred from working with compounders;
interfered with relationships that compounders have with payment processors and social media platforms; and regularly disparaged compounded
medicines as illegal or unsafe<SUP>1</SUP>. There is also ongoing litigation with several states alleging that the Pharmacy Benefit Managers
worked in coordination with Eli Lilly, Sanofi, and Novo Nordisk to distort the market for diabetic treatments to their benefit, at the
expense of diabetics.<SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> https://www.statnews.com/pharmalot/2026/01/14/pharmacy-compounder-antitrust-lilly-novo-weight-obesity/#:~:text=During%20the%20shortages%2C%20Lilly%20and,competition%2C%20although%20the%20outcomes%20varied</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT> h<FONT STYLE="font-size: 10pt">ttps://www.mcaginc.com/post/insulin-pricing-under-fire-what-it-means-for-self-funded-plans</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, advocacy groups in the United Kingdom
(U.K.) have sent a letter to regulators calling out Eli Lilly, AstraZeneca and Merck for allegedly acting in concert with U.K. trade group
the Association of the British Pharmaceutical Industry (ABPI) to drive up drug prices in the U.K<SUP>3</SUP>. These legal challenges and
investigations have generated substantial media attention, which raises concerns about reputational and financial harm to the company
and its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors may disagree about whether an independent
board chair is considered the best governance practice at all companies. However, independent board leadership is clearly at a premium
when a company is in the midst of the kind of legal scrutiny and pressure facing Eli Lilly. We believe a structure where the CEO runs
the business and is accountable to a board led by an independent chair is in the best interests of the company&rsquo;s shareholders for
the following reasons:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Eliminates Structural Conflicts of Interest in Dual Role</U>. The management of a complex global pharmaceutical
company is a full-time job. It is unrealistic &ndash; and needlessly complicated &ndash; to expect one person to perform well as CEO on
top of his or her responsibilities for providing rigorous board oversight. An independent board chair eliminates the structural conflicts
of interest caused by the CEO essentially being his or her own boss and clarifies where the authority of the CEO ends and responsibility
of the independent board members begins.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Significant Governance Concern Resulting from Board Failure to Oversee Material Risks</U>. In light
of potentially material legal, regulatory, financial and reputational risks, as well as controversies and legal challenges facing the
company, we are concerned that the board is not providing sufficiently robust oversight of the company&rsquo;s culture, strategy, and
risk management. Adopting best governance practices, including an independent board chair, should ensure that oversight.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Significant Governance Concern Resulting from Large Insider Ownership</U>. An independent board chair
would be especially useful at Eli Lilly, as its shareholders already have a diluted voice due to the company&rsquo;s largest shareholder
being the company&rsquo;s own foundation. This insider ownership makes it extremely difficult for outside shareholders to exercise their
rights. Having a board chair who is not independent of the company compounds this issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. boards are increasingly recognizing the value
of an independent board chair. As of 2024, approximately 40 percent<SUP>4</SUP> of S&amp;P 500 firms had an independent chair. ISS reported
in September 2025 that 81 percent<SUP>5</SUP> of investors responding to its policy survey indicated that an independent chair is their
preferred model. Moreover, pharmaceutical companies headquartered in Europe are required to have separate roles and have not suffered
as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> h<FONT STYLE="font-size: 10pt">ttps://www.fiercepharma.com/pharma/uk-advocacy-groups-call-investigation-alleged-cartel-scheme-drive-uk-drug-prices-report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> https://www.conference-board.org/publications/Board-Practices-and-Composition-2024-Edition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP> https://www.issgovernance.com/file/policy/active/policy-survey-summary-2025.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="border: Black 1pt solid; text-align: center">This is not a proxy solicitation, to vote your proxy. Please DO NOT send us
your proxy card, as it will not be accepted.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For these reasons we urge you to VOTE FOR ITEM
6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="border: Black 1pt solid; text-align: center">This is not a proxy solicitation, to vote your proxy. Please DO NOT send us
your proxy card, as it will not be accepted.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ff_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ff_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M\>1E//$HJ_[N.WK(_*N/X3GGR44W^[CLK]9%'6YE\-VAO]>CDM(1_'-"PS[
M8R3]*\X\<_M*:#X1A5[3PAK-T)6*P7%S9/:P2$==K2#+8]A75P3X:Y_QM6YJ
M25*@G9U)[>:C'>;]-%U:/SC&XR."@VXMM=+/3U?0\VU[]K;XC:B631;'3]-0
M_=*PF5Q^+<?I7(ZO\7_B?KI8ZCXYU%E)Y6&X,:_3"8K^JN&?!W@OAV,9SH_6
M*J^W5M)7\H?"ON;\SY/$9MC,0[)\J[+_ #W.?NKV]O6+WMY-,QZF60MG\ZCV
MC^[7ZC3ITZ--0IQ44NB5E]R/-<I/5A15DA06"\L: +6HZ'K>CPVMSJ^C7=K'
M?6_GV,EU;-&MQ%DKYB%@-ZY!&X9&0:JX'I2C*,E>+*E&=.5I*S#:O7;6Y_PB
MWQ,T8K(?#?B"TX!5OL4\?&.".!VK'$1PM:/)B%%I]))-/OHS2C3Q%2[IINW;
MH:FE>,OCIIK+%IFK^)/]E"LTGZ,#6E=_'CXXZ#<?V=XEN6\P1AOL^K:.@;:>
MAPRAL'UKX+,O#'P_S:KSRPD85-^:DW3EZ^XTOP.^&,S2A3NV^7S5U^)6_P"%
MYW5T=VL?#;PI=YZLVD!"?Q4BI8_C#X&8C^T/@/X?D)_YXR/'G^=>=4\-,PP\
M;9;G>+HKHI351+_P))_B*.8TY/\ >48OT5OR-34?'GPW\/WW]G>*_P!FA=/N
M?+23[/<321OL=0RMM= <,I!!Z$'(J2W^+WP#3E_@-&O_ &U1OYUX6*X!\3:D
M?]GXCDUTO&U_G%LZOKF!IR<:F'LUNO\ AS4L?CW\"[(?N/@PD9]K2W;^=:UK
M^UE\.+%0ECX%O8<=!#%"N/R-?%YEX*^(6;2_VO-E57]Z55K[G='13SC 4O@I
M6]+$DG[9'A+^#PAJ3?[TT8JO-^V5HHX@\!WF?^FEXH_]EKAH?1RSI_Q<?37I
M"3_-HU?$%+I!_>4;G]LR[/%G\/XQZ&74"?Y)69>_MA>.YLBQ\-Z7!Z%A(Y'_
M (\/Y5]-@/HYY/3DGC<=4GY0C&'XMR?Y'-4XAK/X()>NO^1BZC^T_P#&"_XB
MUJVM1_T[6*?^S9KG=6^*GQ(UO(U/QQJ4BGJJW3(OY+@5^E9)X4\"9#)3HX13
MFOM5'[1_=+W5\HH\VMFF.KZ.=O30PI999W\V>1I&_O.Q)_6FU^AQC&,5&*LE
MT//;;W/Z'/\ @D7_ ,HX?A3_ -B_)_Z5345_-F;_ /(VQ'^.?_I3/[8X=_Y)
M_"?]>J?_ *0AO_!5[5-.T7]C+7-5U>]CM[:#5-/:::9MJJ/M"U\Q_P#!$7]J
M"^^)WQ&^(?PTTJ[OI?#VB^'(=0LX[R8F,3><RL\<1XC# \]SCD5\SAN%LRS/
MB"KF\7RT,/3BF_YY2;2@O1/F?:RZM'Q&;X[ZMXC82E%ZSA9^EIO7YI?->1^>
M6O?\%'_VZ=3\4WFO6W[5WCB%IKV22&*'79%CC4N2%5!\H4#@ #&*[7X@?'C]
ML[_@HW\#/!_P>O/!_BKQWK'@S6M6U"_\11::IB>UD@M_*665%5%:()<$LY!(
ME49)%?TO4R;)<OE2Q2A&G[-WOMIRM6\]6F?B='B3B;.*=?+W4G6]LK*/Q6?/
M&5]=DDFM++770\B\(?L??M.^//@YJ_[07A7X*:Y=>"]#M6N=0\0M;B. 0K]^
M2/>0TRJ.6,88* 2< &O9/A_\4/VF-#_X)G>-O@99_L?03>!YM1BU75/B9J6D
MR0M:+)/"$V-(%69]X1$="2JNPVD<C7'8C+<PY8>W473JPV>\DU:/G>]G;;Y,
MQRG!YYE$IU5A')5J%2UUM!IIS\K6;5[76VZOX!\*?@-\6_C;->+\-/!DU];Z
M<JMJFI33Q6MC8JQPIGN9V2&')Z;W&>V:Z/XW_L8?M*?L[^%=.\??%'X<-!X=
MU9@NF^(]+U*VU'3YV.<*+BUDDC#'!P"03@XSBNZIFF!IXQ864_?;LE9VO:]K
MVLG;6U[VZ'D4L@S:MELL="G>G%7;NKVO;FY;\SBGHY)63TOHSGH?V?OCA-\-
M+KXR?\*HUZ/PK:300RZ]-IKQVS23.$B1'8#S2S$ !-W7FO3O#'_!+3_@H%XP
M\!O\1]#_ &7_ !"VFK;^<J730V]U)'C.Y+:619GR.F$R>V:QQ6>93@X\U6LE
M[W+WUTNM+[75WLNITX'A3B+,I\N'P\F^7GVM[KND];;M.RW=M$SQ'0_"GBCQ
M-XFM_!?ASPY?7VL7=T+6UTNTM7DN)9B<>6L8&XMGC&,U]*?!O]B/_@H)\$?B
M-8^-/!/PFT^37-/>-[S03J&C:IJ$,&]6?S-->665>!S^[WJ/2C,\PRW#T_8X
MF=N=/:^VUVX_"O-V7F/(<GSK&5UB<%3O[.2WY?BWY4I?%*WV4F_(]4_X.&'O
M;[]M_P ->';"S9EA^'6GI9VEO&3\SW=V-BJ.Y(   KYYTK_@F]^V3JD]GI]Q
M\*;72]0U"-7L-%\0>*]+TW4+@,,KMM+JYCFY[?)SVKR<ES+!9=P_A?;RM>-T
MDFV^K=DF[*^KV1]!Q-DN9YUQ?COJL+J,[-MQBDWHE>32N[:*]WT1Y#XW\$^*
M_AMXPU/X?^.M"GTO6M&O9+35-/N0!);S(<,C8)&0?0D5^IG[,_[3/QGT'_@@
MQX[^*T7Q(U9O$GAO5+C3-#UZ>\:2ZLXGNK2-%21\L-@G8+S\HQC&!4\44</C
ML)A9-*2=6G9]U)Z_)HK@/$8S*\QQT4W&4:%5M=I05T_6+O;MJ?!.C?\ !1W]
MO30KQ;_3/VL_''F*V[%QK#S(?JDFY2/J,5](? /]O3]JWXO_ +7]W^T+\)_V
M2)/BAK6M?#O3O"M_!J&EL88;B&"/[1<":-?*A22<2NR,5!23:2N*K,N'\FI4
M9U5:@N5Q<EINXM>73U=[!D?&'$F(Q%/#OFQ,N>,HQE[VRDGYKXD^RM<^+?#/
MPV^)OQF^*,G@3X=_#Z[U;Q%J.H3>7H>A69D*OO)=55<A8UYY)VJ!R<5]??\
M!/W]DC]MWX!?M5^$==M_AMH][HLGB>PMO&D-CJ&C:Y)969FVN9HXI)I;7:&.
M9%"%3U/%=6>9AEM' SPU>=G*#_F^3;7PW>UVKO0\WA7*,ZQ&:4L=AJ2<85$G
M?EL]5S*,9/WK)W:BFTM=-#-_X*?_  +^/7[2'_!3[XEZ%\&_A3KWBFXL[G3;
M>0:/ISS);K]@M]HD<#9&.OWB!BODC6/AEX_T/XCWGPAO?"=Y)XFL=5ETVXT6
MSC^T3_:XW*/"JQ;M[!E(^7.<<9K7(\9@UEM"@IKFC2@VK[+E6K[?/U,>*<MS
M&6=XG%.D^2=>I&+M\34WI'OVTZZ;G0?%_P#9=_:$^ 'A_0_$WQL^$VK^%[7Q
M(9AHO]L0B&6X\K9O_=$[TQYB?>5<YXSS6_\  O\ 82_:T_:0T=?$OPA^"VHZ
MAI,DACAUB\GAL;29QU6.:Y>-)2#V0L:ZZF<993P?UN55>SNTGJ[M-JRMJ]4]
MO78\^CPUGE?,_P"SX4'[9)-Q=E9-)IMMI+1K=K5VWT+MU^S9^U;^R%^T1X5L
MOB#^SAJ4WB.QU&#5M+\.W.G?VA#JJ03*2 +<NLL>X!6VDXR,XXK6_P""EOQ&
M^,OQ8_:@N/'OQV^ EK\-]=U#0[)QX:MU_>"#:?+FF/#&5AG.X*P 4$#'/+1J
MY?CLQHXNC6NW"2C%=4VKRMNK-6UZ^AZ&(P^<97DN(R_$8;E2JP<IM:QDHRM%
M/9W3OHWIY,PO O[ O[6/CZ/39[/X5_V/'K(4Z._BS6+/1OMX)P# M[+$\V3T
MV*V:Y'XS?L\?&S]GSXC-\)?C%\.-2T3Q  K1:=-&)&N%8X5XFC++*K$$!D)!
M((ZC%=5'.,MQ&*="G4O*S>SLTM'9VL[=;-V//Q7#>=8/ K%UJ34&TMU=-JZY
MHI\T;K;F2O\ <7+W]E+]I;3M0\,Z-?? GQ1#?^,EE;POIKZ/*+K45B*AW2''
MF;077YBH&#G.,FNFUK_@GC^VSH7CNX^&-W^SCXAE\06VGPW\VDV,<=Q-]FEW
M;)0(G;<N4925SM92&P1BIGG>4T[<U:.J;WZ)\K=^U]/OMLS2GPKQ#6ORX:6C
M47IK>4>9*V]^76W2ZOJT<+\6/@9\7_@3J]OX?^,?P^U#PWJ%U&9(;'5(Q'-M
M! R4SN7J/O 9K<\9_L@_M.?#OP-_PLWQU\%=:TKPZT*RQ:U>QHEM,C8P8WW8
MDSD?<S6W]IX#EIR]HK5-(_WO3O\ TSE_L+-O:5H>Q=Z*O/\ NK?7M_GIN?NI
M_P $B_\ E'#\*?\ L7Y/_2J:BOYYS?\ Y&V(_P <_P#TIG]A<._\D_A/^O5/
M_P!(1P/_  7L_P"4<GB+_L8M'_\ 2M*^/O\ @W$\O_A=/Q3\[=L_X0:'=MZX
M^T]O>ON,I_Y('$_X_P!8'YAGW_)VL#_@_2H>4?L7R?\ !+N7]JOP'%=:?\7U
MN&\4VG]G-XBN-*.GB[\T>3]I\H;S%YFW.W^6:]H_X(5^-_%EI\;/CQX23Q!<
MR:-;^&;[4(=&FF,EF+D797S?))V;BORDXY7@Y%>]GE/,:F7XI8U1=H4W'EO9
M>^[[]?3H?)\+5<FI9K@'E;FKU*JGS\MVO9QLO=TY=]'U/C^\_P""CO[:NK>$
M?%7@75_CWJUWH_C/2_[.U?2[C8UO#:X(,-K%C9:(4)0B%5!3Y>E?57@/Q[XV
M\9?\&^7Q$?Q?XLU+5FT_QO!96+:A>/,T%LMQ8%84+DD(I)PO09XQ7=FN5Y?@
M*=!T*:C>O2?XI?BEKW>KU/*X?S_-\VK8J.*K.26&KK5]+.7X-Z=EHK(S_P!N
M/]E#QYX)_9?^!O[-/PQUCPGI&AQ^$AXH\72:]XUTW23J>M707,SI=3QO-Y:[
MD0A6"JVT'BG?L-ZQ\&_A1^S=\5OV1_VQ_P!J'X<Q^#?&>E"7P_;Z9XE.JR:5
MJHR/.5+='51D1295OO0CCYB:\[ZU+'9);#TYSJN?M$U%VYE4YOB=EMIHWIH>
MVL#'*^)^;%UZ=/#JDJ33G%RY7147[D6Y?$^;5*[U.F^&'QW^,'@7_@@SXB\:
M>'OB9>7&L:%\2ETO0]<F<SR6=J+FU1?LS3 M#@.Q0@!H]WR[2!CQ7_@C'\6?
MB???\%*/!_\ :?Q"UJ\_MR/48=8^VZG+-]L7['-)^\WL=^'56!.2",BKIX/"
M_P!EYI/D5^:JMMDHII+MKKIU,JV98]9]D5+VK<>2@]]VYN+;[W2MKT^9[+I_
MA6T_9J\*_M@?MZ>&[&.V\46/Q#U'PAX!O%C&[2I+F[5;FZB_NR;;A0K#D%&'
M0FOSR^'WB;Q'H7Q.T;QAHVOWEKJT.MV]Q%JD%TZW"R^:I\SS =VXGJ<Y.:];
M(N7%4\15GK\,/E&G%V_\"E)_,^?XJYL#6P>'I/E^.KII[TZLDGZJ,(I/R/U
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M_P#I6E?(/_!N%9W,_P 7OBO<Q0LR+X)MXV95X#-<,0/J=I_*ON,J=N <3?\
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M:Z7;?QW%T;1KF/C[D=PDT9'?RNHW"M;Q)\;[3P[KNM:&_A^:5M&U+1;-Y%N
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M5% ;GE<<>O-*PSH=Q]:-Q]:0!D]<T;CZT .0_-10 ,#NZ4W!]* #!]*,'TH
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+ !10 44 %% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
